Tumor volume reduction rate is superior to RECIST for predicting the pathological response of rectal cancer treated with neoadjuvant chemoradiation: Results from a prospective study

29Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.

Abstract

The aim of the present study was to compare the tumor volume reduction rate (TVRR), as determined by three-dimensional region-of-interest magnetic resonance volumetry, and Response Evaluation Criteria in Solid Tumors (RECIST) data for predicting the pathological tumor response (PTR) of locally advanced rectal cancer (LARC) following treatment with neoadjuvant chemoradiation (CRT). The current cohort consisted of 105 patients with LARC [clinical tumor stage (cT)3-4 or clinical lymph node stage (cN)+] from a prospective randomized trial who had undergone pre-operative CRT and radical proctectomy. Tumor volumes were measured prior to and following CRT to determine TVRR. Furthermore, receiver operating characteristic (ROC) curves of TVRR and RECIST were constructed to predict the PTR in terms of tumor regression grade (TRG) and downstaging. Values for the area under the ROC curve (AUC) were compared and TVRR cut-off levels were determined. RECIST was used to identify 5 (4.8%) cases of complete response, 44 (41.9%) of partial response, 55 (52.4%) of stable disease and 1 (0.9%) of progressive disease. The mean TVRR was 58.6±24.4%, and a good TRG (0-1) and downstaging occurred in 54 (51.4%) and 59 (56.2%) patients, respectively. In addition, TVRR and RECIST were significantly correlated with TRG and downstaging (P<0.01). The TVRR AUC was significantly larger than that of RECIST for TRG (P=0.020). For downstaging, TVRR also exhibited a larger AUC than RECIST, however, the difference was not significant (P=0.180). The sensitivity and specificity of TVRR in predicting a good TRG were 70.4 and 80.4%, respectively, therefore, the optimal TVRR cut-off value was determined to be 65%. TVRR appeared to be more accurate than RECIST in predicting PTR, particularly for TRG associated with survival. Thus, TVRR may be considered as a novel parameter for evaluating the efficacy of CRT for patients with LARC.

References Powered by Scopus

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

23395Citations
N/AReaders
Get full text

Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach

17380Citations
N/AReaders
Get full text

New guidelines to evaluate the response to treatment in solid tumors

14951Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Predicting cancer outcomes with radiomics and artificial intelligence in radiology

385Citations
N/AReaders
Get full text

Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer

137Citations
N/AReaders
Get full text

The prognostic impact of tumor volume in patients with clinical stage IA non-small cell lung cancer

51Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Xiao, J., Tan, Y., Li, W., Gong, J., Zhou, Z., Huang, Y., … Wang, J. (2015). Tumor volume reduction rate is superior to RECIST for predicting the pathological response of rectal cancer treated with neoadjuvant chemoradiation: Results from a prospective study. Oncology Letters, 9(6), 2680–2686. https://doi.org/10.3892/ol.2015.3101

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 13

81%

Researcher 2

13%

Lecturer / Post doc 1

6%

Readers' Discipline

Tooltip

Medicine and Dentistry 17

100%

Save time finding and organizing research with Mendeley

Sign up for free